Steven Quayle

Steven Quayle has had a long and successful career in the field of biopharmaceuticals. From 2000 to 2007, they were a PhD Student at the British Columbia Cancer Agency. Steven then moved to the Dana-Farber Cancer Institute as a Research Fellow from 2007 to 2012. In 2012, they joined Acetylon Pharmaceuticals, Inc. as a Staff Scientist, eventually becoming Associate Director of Oncology. In 2017, Steven Quayle joined KDAc Therapeutics, Inc. as Associate Director of Translational Biology, and also became Vice President Translational Pharmacology, Senior Director of Pharmacology, and Director of Pharmacology at Cue Biopharma. Throughout their career, they have contributed to the development strategy and preclinical data package for lead candidates in immuno-oncology combinations, overseen studies supporting novel indications and combination therapies, and delivered preclinical data packages supporting the initiation of 6 clinical trials.

Steven Quayle obtained a BSc in Cell Biology from The University of British Columbia between 1996 and 2000. Steven then went on to pursue a PhD in Pathology and Lab Medicine from The University of British Columbia, which they completed in 2006.